Bayer Annual Report 2016: Record Year With Acquisition Of Monsanto.pdf

€46.8 billion (+3.5%)
- EBITDA before special items: €11.3 billion (+10.2%)
- Net income: €4.5 billion (+10.2%)
- Core earnings per share: €7.32 (+7.3%)
- Operating cash flow: €8.3 billion (+20.8%)

- Key Data:
- Sales: €46,769 (+1.5%)
- EBITDA before special items: €11,302 (+10.2%)
- Net income: €4,531 (+10.2%)
- Core earnings per share: €7.32 (+7.3%)
- Net cash provided by operating activities: €9,089 (+31.9%)
- Net financial debt: €11,778 (-32.5%)

- Innovation:
- Research and development expenses: €4,666 (+9.2%)
- Ratio of R&D expenses to sales: Pharmaceuticals (17.0%), Crop Science (11.7%)
- Employees in research and development: 15,229 (+3.8%)

- Employees:
- Number of employees: 115,200 (-1.2%)
- Personnel expenses: €11,357 (+1.6%)
- Proportion of women in senior management: 29%
- Proportion of employees with health insurance: 98%
- Fluctuation (voluntary/total): 4.6%/12.3%
- Hours of vocational and ongoing training per employee: 22.1 (+10.5%)

- Safety & Environmental Protection:
- Recordable Incident Rate (RIR): 0.39 (-7.1%)
- Loss of Primary Containment Incident Rate (LoPC-IR): 0.32 (+45.5%)
- Total energy consumption: 84,494 terajoules (+1.6%)
- Energy efficiency: 6.77 MWh/t (+6.8%)
- Total greenhouse gas emissions: 9.87 million t CO2 equivalents (+1.6%)
- Specific greenhouse gas emissions: 1.54 t CO2 equivalents/t manufactured sales volume (-8.9%)
- Hazardous waste generated: 547 thousand t (+1.1%)
- Water use: 330 million m³ (-4.6%)

- Forecast for 2017: Further growth in sales and earnings.